country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-188134

Copy Link Print Information

CWHM-117

CWHM-117 is an orally active aspartic protease inhibitor with selective activity against Toxoplasma gondii. CWHM-117 inhibits the proliferation of Toxoplasma gondii tachyzoites in human fibroblasts, with an EC₅₀ of 2.00 µM. CWHM-117 delays mortality in an acute mouse model of toxoplasmosis. In a chronic mouse model of toxoplasmosis, CWHM-117 reduces brain cyst burden and prolongs survival. CWHM-117 can be used for research on toxoplasmosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 1505452-80-1
Formel: C₂₃H₂₇N₃O₃
Molecular Weight:393.48

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

CWHM-117 Chemical Structure

CAS. Nr.: 1505452-80-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]

Toxoplasma

2 μM (EC₅₀)

Alle Parasite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HFF	EC50	2.00 μM	Inhibition of intracellular Toxoplasma gondii RH-2F1 tachyzoite proliferation in human foreskin fibroblasts (HFF) incubated for 72 h post-infection, measured by β-galactosidase activity using chlorophenol red-β-D-galactopyranoside (CPRG) as substrate. Inhibition of intracellular Toxoplasma gondii RH-2F1 tachyzoite proliferation in human foreskin fibroblasts (HFF) incubated for 72 h post-infection, measured by β-galactosidase activity using chlorophenol red-β-D-galactopyranoside (CPRG) as substrate.	PMC13435739
HFF	CC₅₀	14.30 μM	Cytotoxicity against human foreskin fibroblasts (HFF) incubated for 72 h, assessed by cell viability measured via resazurin assay. Cytotoxicity against human foreskin fibroblasts (HFF) incubated for 72 h, assessed by cell viability measured via resazurin assay.	PMC13435739

In Vitro

CWHM-117 (0.39-100 μM; 72 h) potently inhibits intracellular proliferation of T. gondii RH-2F1 tachyzoites in HFF cells with an EC₅₀ of 2.00 μM^[1].
CWHM-117 (0.39-100 μM; 72 h) has a CC₅₀ of 14.30 μM against HFF cells, with a selectivity index of 7.15 for T. gondii tachyzoites^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

CWHM-117 (150 mg/kg/day; p.o.; once daily; 10 consecutive days) delays mortality in a murine acute toxoplasmosis model, with treated mice surviving up to day 11 post-infection versus days 7-9 for vehicle controls^[1].
CWHM-117 (150 mg/kg/day; p.o.; once daily; 5 consecutive days) significantly reduces cerebral cyst burden in a murine chronic toxoplasmosis model, demonstrating activity against the latent bradyzoite stage^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Swiss mice (5-6 week old) were infected intraperitoneally with 2 × 10⁵ freshly
egressed T. gondii tachyzoites (RH strain)^[1]
Dosage:

150 mg/kg/day
Administration:

p.o.; once daily; 10 consecutive days
Result:

Delayed mortality, with treated animals surviving up to day 11 post-infection compared to vehicle-treated animals that succumbed between days 7 and 9 post-infection.
Showed no significant weight loss compared to the vehicle group.

Animal Model:

Swiss mice (5-6 week old) were orally
infected with 10 brain cysts of T. gondii (ME-49 strain)^[1]
Dosage:

150 mg/kg/day
Administration:

p.o.; once daily; 5 consecutive days
Result:

Caused a marked, statistically significant reduction in the number of brain cysts compared to the vehicle-treated group.

Chemical Information

CAS. Nr. 1505452-80-1
Molecular Weight 393.48
Formel C₂₃H₂₇N₃O₃
SMILES

N=C(NC1(C2=CC=C(OC)C=C2)C3=CC=C(OC)C=C3)N(C4CCCCC4)C1=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Santos GPd, et al. In vitro and in vivo activity of the aspartic protease inhibitor CWHM-117 against Toxoplasma gondii. Antimicrob Agents Chemother. 2026 Aug 5;70(8):e0037026.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen